Nightingale opens Singapore laboratory
Translation: Original published in Finnish on 11/29/2024 at 12:56 pm EET.
According to the release, the opening of the laboratory will be celebrated on Monday, December 2, and the company expects the first healthcare samples to arrive at the laboratory during Q1/2025. This news was fully expected after the confirmation of the regulatory approvals and has no impact on our view of the company. We have previously commented on the opening of the laboratory and its impact on the company's investment story in more detail here.
Nightingale Health
Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.
Read more on company pageKey Estimate Figures23.09
2024 | 25e | 26e | |
---|---|---|---|
Revenue | 4.4 | 6.5 | 10.8 |
growth-% | 4.21 % | 50.10 % | 65.10 % |
EBIT (adj.) | -18.6 | -17.9 | -15.5 |
EBIT-% (adj.) | -426.62 % | -273.48 % | -143.18 % |
EPS (adj.) | -0.29 | -0.28 | -0.23 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | - | - | - |
EV/EBITDA | - | - | - |